Technology ID
TT-0119
Description
We aim to develop AAVs that can effectively cross the blood-brain barrier and deliver therapeutic genetic materials or tools to target brain cells for the treatment of brain diseases.
Content
Targeted AAV Screening: Identify AAV capsids capable of crossing the BBB and delivering to specific brain cells while exhibiting limited off-target expression, reduced systemic organ toxicity, and low immunogenicity
Non-Invasive Delivery Method: Achieve non-invasive delivery to brain cells through IV injection, offering a patient-friendly treatment approach
Strategic Partnership for AAV Development: Engage in a strategic partnership with Cure Genetics to co-develop and license AAV(s), utilizing a primate model
Inventors
Applicable Industries
Potential Application
Technology Focus
TRL
Images
